A5007537451- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Blood transfusion and management
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Blood groups and transfusion
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Platelet Disorders and Treatments
- Erythrocyte Function and Pathophysiology
- Advanced Proteomics Techniques and Applications
- Glycosylation and Glycoproteins Research
- Cholinesterase and Neurodegenerative Diseases
- S100 Proteins and Annexins
- Mitochondrial Function and Pathology
- Acute Myocardial Infarction Research
- Blood donation and transfusion practices
- Blood disorders and treatments
- Clusterin in disease pathology
- Maternal and fetal healthcare
- Pregnancy and preeclampsia studies
- Mass Spectrometry Techniques and Applications
- Hemodynamic Monitoring and Therapy
- Heat shock proteins research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Immune Cell Function and Interaction
Sahlgrenska University Hospital
2001-2024
University of Gothenburg
2011-2024
Valley Hospital
1998
Karolinska Institutet
1998
<h3>Objectives</h3> To study the diagnostic potential of 42 amino acid form β-amyloid (β-amyloid<sub>(1-42)</sub>) in cerebrospinal fluid (CSF) as a biochemical marker for Alzheimer disease (AD), intra-individual biological variation CSF-β-amyloid<sub>(1-42)</sub>level patients with AD, and possible effects differential binding between apolipoprotein E isoforms on CSF-β-amyloid<sub>(1-42)</sub>levels. <h3>Design</h3> A 20-month prospective follow-up study. <h3>Setting</h3> Community...
The standardization and clinical validation of the measurement β–amyloid. (Aβ42) in cerebrospinal fluid (CSF), plasma urine is described using a commercially available sandwich–type ELISA with 2 IF12 3D6 as monoclonal antibodies. INNOTEST™ β–amyloid(1–42) allows specific reliable (1–42) amyloid peptides CSF plasma. Aβ42 concentrations serum were below detection limit. In plasma, no differences found levels between controls patients different neurodegenerative disorders (Alzheimer's disease...
We investigated blood-brain barrier (BBB) function in relation to Alzheimer9s disease (AD) and vascular dementia (VAD) the very elderly. Sixty-five 85-year-old persons from a population-based sample were followed for 3 years; 29 demented at age 85 (13 with AD, 14 VAD, 2 other dementias), 7 developed during follow-up, remained nondemented. CSF/serum albumin ratio was used as measure of BBB function. Dementia defined according DSM-III-R, AD NINCDS-ADRDA criteria, VAD NINDS-Association...
<h3>OBJECTIVES</h3> Biochemical markers for Alzheimer's disease would be of great value, especially to help in diagnosis early the course disease. A pronounced increase CSF tau protein (CSF-tau) is found most patients with However, specificity has further studied, as an CSF-tau also been other dementias, vascular dementia. As previous studies have based on selected inpatients, it was considered special interest examine diagnostic potential a community population sample consecutive Such...
Urine is a complex mixture of proteins and waste products challenging biological fluid for biomarker discovery. Previous proteomic studies have identified more than 2800 urinary but analyses aimed at unraveling glycan structures glycosylation sites glycoproteins are lacking. Glycoproteomic characterization remains difficult because the complexity found mainly on asparagine (N-linked) or serine/threonine (O-linked) residues. We developed glycoproteomic approach that combines efficient...
Potential cerebrospinal fluid (CSF) markers for Alzheimer's disease (AD) include tau protein, the 42 amino-acid form of amyloid ß (amyloid ß(1-42)) and apolipoprotein E (apoE). To study new aspects these protein markers, we examined consecutive CS
<h3>OBJECTIVES</h3> To study the association of apoE genotypes with dementia and cerebrovascular disorders in a population based sample 85 year old people. <h3>METHODS</h3> A representative people (303 non-demented, 109 demented) were given neuropsychiatric medical examination head CT. The isoforms determined. Dementia was diagnosed according to DSM-III-R. <h3>RESULTS</h3> At age 85, carriers ε4 allele had an increased odds ratio (OR) for (1.9; p<0.01) its subtypes Alzheimer's disease...
A preparative proteomic approach, involving liquid phase isoelectric focusing (IEF) in combination with one-dimensional electrophoresis and electroelution followed by mass spectrometry database searches, was found to be an important tool for identifying low-abundant proteins (μg/L) human cerebrospinal fluid (CSF) membrane frontal cortex. Several neuron-related proteins, such as amyloid precursor-like protein, chromogranins B, glial fibrillary acid β-trace, transthyretin, ubiquitin, cystatin...
Apolipoprotein E (ApoE) has been implicated in the pathogenesis of Alzheimer's disease (AD). ApoE is synthesized within brain and suggested to be involved re-utilization membrane lipids during neuronal repair remyelination after injury. Spherical ApoE-containing lipoprotein particles are found cerebrospinal fluid (CSF). To study further pathogenetic role degenerative disorders, we analysed CSF. A significant (p < 0.001) reduction CSF (1.5 +/- 1.2 ng ml-1) was AD compared with controls (5.0...
OBJECTIVE: Dual antiplatelet therapy with ticagrelor and aspirin is associated an increased risk of perioperative bleeding complications. Current guidelines recommend therefore discontinuation 5 days before surgery to allow sufficient recovery platelet function. It not known how the time varies between individual patients after ticagrelor. METHODS: Twenty-five accepted for urgent coronary artery bypass treated were included in a prospective observational study. Platelet aggregation was...
Apolipoprotein E (apoE) has been suggested to play a role in regenerative processes the brain after trauma, and also pathogenesis of Alzheimer''s disease (AD). We examined cerebrospinal fluid (CSF) apoE material consisting 23 patients with early-onset AD (EAD), 31 late-onset (LAD), 16 frontal-lobe dementia (FLD), 25 vascular (VAD) controls. CSF-apoE was decreased all EAD (1.8 ± 1.1 mg/l; p < 0.0005), LAD(2.5 0.9mg/l; 0.0005),VAD (2.3 1.4mg/l; 0.0005) FLD (3.0 1.3 0.05) compared control...
Storage impairs platelet function. It was hypothesized that multiple electrode aggregometry in vitro could be used to follow aggregability concentrates over time and the results predict efficacy of transfusion an ex vivo model. In assessed apheresis pooled buffy coat (BCs) (n = 13 each) using with different agonists 1, 3, 5 7 days after preparation. model, whole blood samples from nine healthy volunteers were collected every second day. The supplemented stored platelets (+146 × 109 l−1) same...
Temporarily improved platelet reactivity may reduce the bleeding in patients on antiplatelet therapy who have ongoing or are need of acute surgery. Adrenaline can bind to adrenergic α2A-receptors platelets and potentially enhance reactivity.To assess if adrenaline improve adenosine diphosphate (ADP)-induced aggregation activation blood samples from dual with acetylsalicylic acid (ASA) ADP-receptor antagonist ticagrelor.Blood were collected a total forty coronary syndrome ASA ticagrelor....